Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Kurz, Katharina ^a   Herold, Manfred ^a   Russe, Elisabeth ^a   Klotz, Werner ^a   Weiss, Guenter ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NEOPTERIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; SALAZOSULFAPYRIDINE; VITAMIN D; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; NONPARAMETRIC TEST; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; ARTHRITIS, RHEUMATOID; BLOOD; COMBINATION DRUG THERAPY; MIDDLE AGED;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPTERIN; OSTEOPROTEGERIN; RANK LIGAND;

EID: 84947976581     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/276969     Document Type: Article

References (45)

1. I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis,"The New England Journal ofMedicine, vol. 365, no. 23, pp. 2205-2219, 2011.
2. C. Christodoulou and E. H. Choy, "Joint inflammation and cytokine inhibition in rheumatoid arthritis," Clinical and Experimental Medicine, vol. 6, no. 1, pp. 13-19, 2006.
3. E. H. S. Choy and G. S. Panayi, "Cytokine pathways and joint inflamation in rheumatoid arthritis," The New England Journal of Medicine, vol. 344, no. 12, pp. 907-916, 2001.
4. J. D. Cañete, S. E. Martínez, J. Farrés et al., "Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies," Annals of the Rheumatic Diseases, vol. 59, no. 4, pp. 263-268, 2000.
5. M. Feldmann, "The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target," Journal of the Royal College of Physicians of London, vol. 30, no. 6, pp. 560-570, 1996.
6. A. P. Cope, D. Aderka, M. Doherty et al., "Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases," Arthritis and Rheumatism, vol. 35, no. 10, pp. 1160-1169, 1992.
7. P. Barrera, A. M. Boerbooms, E. M. Janssen et al., "Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis," Arthritis & Rheumatism, vol. 36, no. 8, pp. 1070-1079, 1993.
8. G. Steiner, A. Studnicka-Benke, G. Witzmann, E. Hofler, and J. Smolen, "Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis," Journal of Rheumatology, vol. 22, no. 3, pp. 406-412, 1995.
9. M. Ziolkowska, M. Kurowska, A. Radzikowska et al., "High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment,"Arthritis&Rheumatism, vol. 46, no. 7, pp. 1744-1753, 2002.
10. M. Rauner, W. Sipos, and P. Pietschmann, "Osteoimmunology," International Archives of Allergy and Immunology, vol. 143, no. 1, pp. 31-48, 2007.
11. B. M. Thomson, G. R. Mundy, and T. J. Chambers, "Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption," The Journal of Immunology, vol. 138, no. 3, pp. 775-779, 1987.
12. S. R. Goldring and E. M. Gravallese, "Pathogenesis of bone lesions in rheumatoid arthritis," Current Rheumatology Reports, vol. 4, no. 3, pp. 226-231, 2002.
13. L. C. Hofbauer, A. E. Heufelder, and R. G. Erben, "Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis,"The Journal of Rheumatology, vol. 28, no. 4, pp. 685-687, 2001.
14. H. Takayanagi, H. Iizuka, T. Juji et al., "Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis," Arthritis and Rheumatism, vol. 43, no. 2, pp. 259-269, 2000.
15. M. C. Walsh and Y. Choi, "Biology of the RANKL-RANKOPG system in immunity, bone, and beyond," Frontiers in Immunology, vol. 5, article 511, 2014.
16. M. Skoumal, G. Kolarz, G. Haberhauer, W. Woloszczuk, G. Hawa, and A. Klingler, "Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis," Rheumatology International, vol. 26, no. 1, pp. 63-69, 2005.
17. M. Skoumal, G. Kolarz, W. Woloszczuk, G. Hawa, and A. Klingler, "Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 63, no. 2, pp. 216-217, 2004.
18. C. Monaco, J. Nanchahal, P. Taylor, and M. Feldmann, "Anti-TNF therapy: past, present and future," International Immunology, vol. 27, no. 1, pp. 55-62, 2015.
19. J. S. Smolen and D. Aletaha, "Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges," Nature Reviews Rheumatology, vol. 11, pp. 276-289, 2015.
20. M. Vis, E. A. Havaardsholm, G. Haugeberg et al., "Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 65, no. 11, pp. 1495-1499, 2006.
21. H. Marotte, B. Pallot-Prades, L. Grange, P. Gaudin, C. Alexandre, and P. Miossec, "A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab," Arthritis Research and Therapy, vol. 9, no. 3, article R61, 2007.
22. B. Seriolo, S. Paolino, A. Sulli, V. Ferretti, andM. Cutolo, "Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis," Annals of the New York Academy of Sciences, vol. 1069, pp. 420-427, 2006.
23. U. Lange, J. Teichmann, U. Müller-Ladner, and J. Strunk, "Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective openlabel pilot study," Rheumatology, vol. 44, no. 12, pp. 1546-1548, 2005.
24. I. González-Alvaro, A. M. Ortiz, E. G. Tomero et al., "Baseline serumRANKLlevels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists," Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1675-1678, 2007.
25. C. Murr, B. Widner, B. Wirleitner, and D. Fuchs, "Neopterin as a marker for immune system activation," Current Drug Metabolism, vol. 3, no. 2, pp. 175-187, 2002.
26. G. Reibnegger, D. Egg, D. Fuchs et al., "Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis," Arthritis and Rheumatism, vol. 29, no. 9, pp. 1063-1070, 1986.
27. P. Hannonen, S. Tikanoja, M. Hakola, T.Möttönen, L. Viinikka, andM. Oka, "Urinary neopterin index as a measure of rheumatoid activity," Scandinavian Journal of Rheumatology, vol. 15, no. 2, pp. 148-152, 1986.
28. K. Schroecksnadel, S. Kaser, M. Ledochowski et al., "Increased degradation of tryptophan in blood of patients with rheumatoid arthritis,"The Journal of Rheumatology, vol. 30, no. 9, pp. 1935-1939, 2003.
29. K. Kurz, M. Herold, C. Winkler, W. Klotz, E. Russe, and D. Fuchs, "Effects of adalimumab therapy on disease activity and interferon-gamma-mediated biochemical pathways in patients with rheumatoid arthritis," Autoimmunity, vol. 44, no. 3, pp. 235-242, 2011.
30. L. E. D'agostino, F. Ventimiglia, J. A. Verna et al., "Correlation between DAS-28 and neopterin as a biochemical marker of immune system activation in early rheumatoid arthritis," Autoimmunity, vol. 46, no. 1, pp. 44-49, 2013.
31. D. Arshadi, B. Nikbin, Y. Shakiba, A. Kiani, A. R. Jamshidi, and M. T. Boroushaki, "Plasma level of neopterin as a marker of disease activity in treated rheumatoid arthritis patients: association with gender, disease activity and anti-CCP antibody," International Immunopharmacology, vol. 17, no. 3, pp. 763-767, 2013.
32. K. Schroecksnadel, C. Winkler, C. Duftner, B. Wirleitner, M. Schirmer, and D. Fuchs, "Tryptophan degradation increases with stage in patients with rheumatoid arthritis," Clinical Rheumatology, vol. 25, no. 3, pp. 334-337, 2006.
33. K. Schroecksnadel, T. B. Grammer, B. O. Boehm, W. März, and D. Fuchs, "Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers," Thrombosis and Haemostasis, vol. 103, no. 5, pp. 926-935, 2010.
34. K. Schroecksnadel, M. Fiegl, K. Prassl, C. Winkler, H. A. Denz, and D. Fuchs, "Diminished quality of life in patients with cancer correlates with tryptophan degradation," Journal of Cancer Research and Clinical Oncology, vol. 133, no. 7, pp. 477-485, 2007.
35. R. Sucher, K. Schroecksnadel, G. Weiss, R. Margreiter, D. Fuchs, and G. Brandacher, "Neopterin, a prognostic marker in human malignancies," Cancer Letters, vol. 287, no. 1, pp. 13-22, 2010.
36. N. Takahashi, G. R. Mundy, andG.D. Roodman, "Recombinant human interferon-γ inhibits formation of human osteoclastlike cells," Journal of Immunology, vol. 137, no. 11, pp. 3544-3549, 1986.
37. M. Tunyogi-Csapo, K. Kis-Toth, M. Radacs et al., "Cytokinecontrolled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption," Arthritis and Rheumatism, vol. 58, no. 8, pp. 2397-2408, 2008.
38. H. Marotte, W. Maslinski, and P. Miossec, "Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response," Arthritis Research &Therapy, vol. 7, no. 1, pp. R149-R155, 2005.
39. U. Boehm, T. Klamp, M. Groot, and J. C. Howard, "Cellular responses to interferon-γ," Annual Review of Immunology, vol. 15, pp. 749-795, 1997.
40. J. Zupan, M. Jeras, and J. Marc, "Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts," Biochemia Medica, vol. 23, no. 1, pp. 43-63, 2013.
41. H. Kohara, H. Kitaura, Y. Fujimura et al., "IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions," Immunology Letters, vol. 137, no. 1-2, pp. 53-61, 2011.
42. P. Fardellone, A. Séjourné, J. Paccou, and V. Goëb, "Bone remodelling markers in rheumatoid arthritis," Mediators of Inflammation, vol. 2014, Article ID 484280, 5 pages, 2014.
43. S. Khosla, H. M. Arrighi, L. J. Melton III et al., "Correlates of osteoprotegerin levels in women and men," Osteoporosis International, vol. 13, no. 5, pp. 394-399, 2002.
44. S. Kudlacek, B. Schneider, W. Woloszczuk, P. Pietschmann, and R. Willvonseder, "Serumlevels of osteoprotegerin increase with age in a healthy adult population," Bone, vol. 32, no. 6, pp. 681-686, 2003.
45. D. Dénarié, E. Constant, T. Thomas, and H. Marotte, "Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients?" Mediators of Inflammation, vol. 2014, Article ID 537324, 7 pages, 2014.